G. J. Alangaden, E. K. Manavathu, S. B. Vakulenko, N. M. Zvonok, and S. A. Lerner, Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients, Antimicrobial Agents and Chemotherapy, vol.39, issue.8, pp.1700-1703, 1995.
DOI : 10.1128/AAC.39.8.1700

S. Bazile, N. Moreau, D. Bouzard, and M. Essiz, Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolones., Antimicrobial Agents and Chemotherapy, vol.36, issue.12, pp.2622-2627, 1992.
DOI : 10.1128/AAC.36.12.2622

A. B. Bloch, G. M. Cauthen, I. M. Onorato, G. Kenneth, G. Dansbury et al., Nationwide Survey of Drug-Resistant Tuberculosis in the United States, JAMA: The Journal of the American Medical Association, vol.271, issue.9, pp.665-671, 1994.
DOI : 10.1001/jama.1994.03510330043032

S. J. Cavalieri, J. R. Biehle, W. E. Sanders, and J. , Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis, Antimicrobial Agents and Chemotherapy, vol.39, issue.7, pp.1542-1545, 1995.
DOI : 10.1128/AAC.39.7.1542

A. M. Dhople and M. A. Ibanez, In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae, Antimicrobial Agents and Chemotherapy, vol.39, issue.9, pp.2116-2119, 1995.
DOI : 10.1128/AAC.39.9.2116

T. R. Frieden, T. Sterling, A. Pablos-mendez, J. O. Kilburn, G. M. Gauthen et al., The Emergence of Drug-Resistant Tuberculosis in New York City, New England Journal of Medicine, vol.328, issue.8, pp.521-526, 1993.
DOI : 10.1056/NEJM199302253280801

K. P. Fu, S. C. Lafredo, B. Foleno, D. M. Isaacson, J. F. Barett et al., In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin., Antimicrobial Agents and Chemotherapy, vol.36, issue.4, pp.860-866, 1992.
DOI : 10.1128/AAC.36.4.860

S. D. Goodwin, H. A. Gallis, A. T. Chow, F. A. Wong, S. C. Flor et al., Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection., Antimicrobial Agents and Chemotherapy, vol.38, issue.4, pp.799-804, 1994.
DOI : 10.1128/AAC.38.4.799

I. Hayakawa, S. Atarashi, S. Yokohama, M. Imamura, K. Sakano et al., Synthesis and antibacterial activities of optically active ofloxacin., Antimicrobial Agents and Chemotherapy, vol.29, issue.1, pp.163-164, 1986.
DOI : 10.1128/AAC.29.1.163

L. B. Heifets, Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against mycobacterium tuberculosis and mycobacterium avium complex, Tubercle, vol.68, issue.4, pp.267-276, 1987.
DOI : 10.1016/0041-3879(87)90067-5

M. Immamura, S. Shibamura, I. Hayakawa, and Y. Osada, Inhibition of DNA gyrase by optically active ofloxacin., Antimicrobial Agents and Chemotherapy, vol.31, issue.2, pp.325-327, 1987.
DOI : 10.1128/AAC.31.2.325

M. D. Iseman, Treatment of multidrug-resistant tuberculosis, N. Engl. J. Med, vol.329, pp.784-791, 1993.
DOI : 10.1007/978-94-011-4084-3_11

B. Ji, N. Lounis, C. Truffot-pernot, and J. Grosset, In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis, Antimicrobial Agents and Chemotherapy, vol.39, issue.6, pp.1341-1344, 1995.
DOI : 10.1128/AAC.39.6.1341

B. Ji, E. G. Perani, C. Petinom, L. N. Deli, and J. Grosset, Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy., Antimicrobial Agents and Chemotherapy, vol.38, issue.4, pp.662-667, 1994.
DOI : 10.1128/AAC.38.4.662

S. P. Klemens, C. A. Sharpe, M. C. Rogge, and M. H. Cynamon, Activity of levofloxacin in a murine model of tuberculosis., Antimicrobial Agents and Chemotherapy, vol.38, issue.7, pp.1476-1479, 1994.
DOI : 10.1128/AAC.38.7.1476

V. Lalande, C. Truffot-pernot, A. Paccaly-moulin, J. Grosset, and B. Ji, Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice., Antimicrobial Agents and Chemotherapy, vol.37, issue.3, pp.407-413, 1993.
DOI : 10.1128/AAC.37.3.407

C. N. Lee and L. B. Heifets, Determination of Minimal Inhibitory Concentrations of Antituberculosis Drugs by Radiometric and Conventional Methods, American Review of Respiratory Disease, vol.136, issue.2, pp.349-352, 1987.
DOI : 10.1164/ajrccm/136.2.349

N. Mor, J. Vanderkolk, and L. Heifets, Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages., Antimicrobial Agents and Chemotherapy, vol.38, issue.5, pp.1161-1164, 1994.
DOI : 10.1128/AAC.38.5.1161

M. Nakashima, T. Uematsu, M. Kanamura, O. Okazaki, S. Hashimoto et al., Pharmacokinetics of DR-3355, a new quinolone, in healthy volunteers, abstr. 951, p. 278, Program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1988.

H. C. Neu and N. Chin, In vitro activity of S-ofloxacin., Antimicrobial Agents and Chemotherapy, vol.33, issue.7, pp.1105-1107, 1989.
DOI : 10.1128/AAC.33.7.1105

A. Pascual, I. Garcia, and E. J. Perea, Fluorometric measurement of ofloxacin uptake by human polymorphonuclear leukocytes., Antimicrobial Agents and Chemotherapy, vol.33, issue.5, pp.653-656, 1990.
DOI : 10.1128/AAC.33.5.653

A. Pascual, I. Garcia, and E. J. Perea, Uptake and intracellular activity of an optically active ofloxacin isomer in human neutrophils and tissue culture cells., Antimicrobial Agents and Chemotherapy, vol.34, issue.2, pp.277-280, 1990.
DOI : 10.1128/AAC.34.2.277

N. Rastogi, Mycobacteria as intracellular pathogens: current notions of pathogenicity, virulence, and drug resistance and their relation to effective therapy Antimicrobial agents and intracellular pathogens, pp.245-300, 1993.

N. Rastogi and M. C. Blom-potar, Intracellular Bactericidal Activity of Ciprofloxacin and Ofloxacin Against Mycobacterium tuberculosis H37Rv Multiplying in the J-774 Macrophage Cell Line, Zentralblatt f??r Bakteriologie, vol.273, issue.2, pp.195-199, 1990.
DOI : 10.1016/S0934-8840(11)80249-5

N. Rastogi and K. S. Goh, In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin., Antimicrobial Agents and Chemotherapy, vol.35, issue.9, pp.1933-1936, 1991.
DOI : 10.1128/AAC.35.9.1933

N. Rastogi, K. S. Goh, and H. L. David, Drug susceptibility testing in tuberculosis: A comparison of the proportion methods using Lowenstein-Jensen, middlebrook 7H10 and 7H11 agar media and a radiometric method, Research in Microbiology, vol.140, issue.5, pp.405-417, 1989.
DOI : 10.1016/0923-2508(89)90016-8

N. Rastogi, K. S. Goh, P. Ruiz, and M. Casal, In vitro activity of roxithromycin against the Mycobacterium tuberculosis complex, Antimicrobial Agents and Chemotherapy, vol.39, issue.5, pp.1162-1165, 1995.
DOI : 10.1128/AAC.39.5.1162
URL : https://hal.archives-ouvertes.fr/pasteur-00925376

N. Rastogi, A. Kochi, B. Vareldzis, K. Styblo, J. T. Crawford et al., Emergence of multiple-drug-resistant tuberculosis: fundamental and applied research aspects, global issues and current strategies, Research in Microbiology, vol.144, issue.2, pp.103-158, 1993.
DOI : 10.1016/0923-2508(93)90022-T

N. Rastogi and V. Labrousse, Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex., Antimicrobial Agents and Chemotherapy, vol.35, issue.3, pp.462-470, 1991.
DOI : 10.1128/AAC.35.3.462

N. Rastogi, V. Labrousse, and A. Bryskier, Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages, Antimicrobial Agents and Chemotherapy, vol.39, issue.4, pp.976-978, 1995.
DOI : 10.1128/AAC.39.4.976
URL : https://hal.archives-ouvertes.fr/pasteur-00925375

N. Rastogi, V. Labrousse, K. S. Goh, J. P. Carvalho, and . Sousa, Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages., Antimicrobial Agents and Chemotherapy, vol.35, issue.12, pp.2473-2480, 1991.
DOI : 10.1128/AAC.35.12.2473

N. Rastogi, B. C. Ross, B. Dwyer, K. S. Goh, S. Clavel-sérès et al., Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain ofMycobacterium tuberculosis, European Journal of Clinical Microbiology & Infectious Diseases, vol.29, issue.Supplement 1, pp.901-907, 1993.
DOI : 10.1007/BF01962370

L. W. Riley, Drug-Resistant Tuberculosis, Clinical Infectious Diseases, vol.17, issue.Supplement 2, pp.442-446, 1993.
DOI : 10.1093/clinids/17.Supplement_2.S442

H. Saito, K. Sato, H. Tomioka, and S. Dekio, In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR3355), Tubercle and Lung Disease, vol.76, issue.5, pp.377-380, 1995.
DOI : 10.1016/0962-8479(95)90001-2

S. H. Siddiqi, J. E. Hawkins, and A. Laszlo, Interlaboratory drug susceptibility testing of Mycobacterium tuberculosis by a radiometric procedure and two conventional methods, J. Clin. Microbiol, vol.22, pp.919-923, 1985.

S. H. Siddiqi, J. P. Libonati, and G. Middlebrook, Evaluation of a rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis, J. Clin. Microbiol, vol.13, pp.908-912, 1981.

P. S. Skinner, S. K. Furney, D. A. Kleinert, and I. A. Orme, Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis, Antimicrobial Agents and Chemotherapy, vol.39, issue.3, pp.750-753, 1995.
DOI : 10.1128/AAC.39.3.750

M. Tanaka, M. Otsuki, T. Une, and T. Nishino, In-vitro and in-vivo activity of DR-3355, an optically active isomer of ofloxacin, Journal of Antimicrobial Chemotherapy, vol.26, issue.5, pp.659-666, 1990.
DOI : 10.1093/jac/26.5.659

M. Tsukamura, E. Nakamura, S. Oshii, and H. Amano, Therapeutic effect of a new antibacterial substance ofloxacin (DL-8280) on pulmonary tuberculosis, Am. Rev. Respir. Dis, vol.131, pp.352-356, 1985.

T. Une, T. Fujimoto, K. Sato, and Y. Osada, In vitro activity of DR-3355, an optically active ofloxacin., Antimicrobial Agents and Chemotherapy, vol.32, issue.9, pp.1336-1340, 1988.
DOI : 10.1128/AAC.32.9.1336